Fingerprint
Dive into the research topics of 'Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically